Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SUDA Pharmaceuticals - GM presentation (ASX:SUD)

To view the presentation, download the attached PDF.

Sequoia Financial Group - Change of Director's Interest Notice - John Larsen (ASX:SEQ)

To view the Change of Director’s Interest Notice, download the attached PDF.

Sequoia Financial Group - Change of Director's Interest Notice - Charles Sweeney (ASX:SEQ)

To view the Change of Director’s Interest Notice, download the attached PDF.

Sequoia Financial Group - Change of Director's Interest Notice - Garry Crole (ASX:SEQ)

To view the Change of Director’s Interest Notice, download the attached PDF.

Sequoia Financial Group - Application for quotation of securities (ASX:SEQ)

To view the Application for quotation of +securities, download the attached PDF.

Sequoia Financial Group - Update - Dividend/Distribution (ASX:SEQ)

To view the Notification of dividend / distribution, download the attached PDF.

Sequoia Financial Group - Confirmation of DRP Issue Price for 2021 Final Dividend (ASX:SEQ)

Sequoia Financial Group Ltd (ASX: SEQ) (Company or Sequoia) advises that the issue price of shares to be issued to shareholders who have elected to participate in Sequoia’s Dividend Reinvestme...read more

SUDA Pharmaceuticals - Investor Presentation (ASX:SUD)

To view the presentation, download the attached PDF.

SUDA Pharmaceuticals - Preliminary Final Report (ASX:SUD)

To view the report, download the attached PDF.

Sequoia Financial Group - Change in substantial holding (ASX:SEQ)

To view the Notice of change of interests of substantial holder, download the attached PDF.

SUDA Pharmaceuticals - Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB (ASX:SUD)

SUDA enhances its Scientific Advisory Board (SAB) to gain expert guidance on the clinical development of allogenic cell therapies Dr Reuben Benjamin, who leads the plasma cell disorder service an...read more

Sequoia Financial Group - Application for quotation of securities (ASX:SEQ)

To view the Application for quotation of +securities, download the attached PDF.

SUDA Pharmaceuticals signs Licence and Distribution Agreement with STADA (ASX:SUD)

SUDA grants an exclusive Licence for the rights to ZolpiMist® for commercialisation in Australia to STADA Pharmaceuticals, part of the international Pharmaceutical Company, STADA Group SUDA t...read more

SUDA Pharmaceuticals - ZolpiMist Update (ASX:SUD)

SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, advises that Mitsubishi Tanabe Pha...read more